Aims/hypothesis. Adiponectin, an adipocytokine known to be down-regulated in obesity-linked disorders, is considered to be a potential key mediator of insulin sensitivity. In this study, we asked whether adiponectin is able to regulate ten selected genes possibly associated with insulin sensitivity in human skeletal muscle cells. Methods. To this end, we treated in vitro differentiated human myotubes with the culture supernatant of HEK293 cells stably transfected with human recombinant adiponectin and assessed gene expression by RT-PCR. Intracellular adiponectin protein was quantified by radioimmunoassay and visualized by Western blotting. Results. In contrast to the control supernatant, the adiponectin-containing supernatant consistently induced expression of adiponectin mRNA in human myotubes from eight different donors (mean increase: 90-fold over control; n=8, p<0.001). This increase in mRNA was paralleled by a rise in intracellular adiponectin protein (mean increase: 8.3-fold over control; n=4, p<0.05). Expression of the other nine candidate genes was not altered. In human skin fibroblasts and HepG2 cells, the adiponectin-enriched supernatant did not induce relevant amounts of adiponectin mRNA. Conclusions/interpretation. In conclusion, we show here that adiponectin gene expression is specifically inducible in skeletal muscle cells. [Diabetologia (2003) 46:956-960] 
sclerosis. In this context, hypertrophic adipose tissue is thought to influence other peripheral tissues (muscle, liver, pancreas) by dysregulated secretion of fatty acids and a limited number of hormone-like polypeptides, now better known as adipocytokines. Among these, leptin and adiponectin were recently shown to have insulin-sensitizing activities [1] .
Adiponectin is a protein with a molecular weight of about 30,000 M r which is exclusively and abundantly produced by adipocytes and circulates at high concentrations in the bloodstream (0.01% of total plasma protein). Its plasma concentrations are reported to be decreased in obesity, insulin resistance, hyperinsulinaemia, and coronary heart disease (for review, see [2] ). Insights into its molecular function were derived from studies in mice. Adiponectin enhances the insulin-dependent suppression of hepatic gluconeogenesis, thereby lowering plasma glucose concentrations [3, 4] . Furthermore, adiponectin is able to increase clearObesity becomes increasingly evident in Western industrialized countries due to malnutrition and a sedentary lifestyle combined with a genetic predisposition. It is a major health problem because of its close association with modern civilization diseases, like insulin resistance, Type 2 diabetes, hypertension, and athero-ance of plasma free fatty acids, probably by induction of fatty acid transport protein-1 (FATP-1) gene expression in muscle [5, 6] . Finally, anti-steatotic effects on liver and muscle due to increased fatty acid oxidation were shown and could be mediated by peroxisome proliferator-activated receptor (PPAR)-α [1, 5] .
Due to these beneficial effects of adiponectin, the regulation of its gene is currently being investigated. During in vitro studies, fat cell expression of adiponectin was shown to be repressed by factors known to be increased in insulin resistance, such as insulin [7] , tumour necrosis factor-α [7, 8] , glucocorticoids [7, 9] , and β-adrenergic agonists [10, 11] . In contrast, the only stimulus for adiponectin gene expression in adipocytes known to date is the pharmacological activation of PPARγ by thiazolidinediones [12, 13] .
The objective of this study was to examine whether adiponectin is able to induce in primary human myotubes genes of potential downstream targets, like FATP-1 and PPARα, as well as other genes related to insulin sensitivity in humans.
Materials and methods
Tissue sampling and cell culture. Primary human skeletal muscle cells were grown from satellite cells obtained from percutaneous needle biopsies carried out on the lateral portion of the quadriceps femoris (vastus lateralis) muscle [14] . The eight donors were normal weight healthy Caucasian subjects (2 men/ 6 women; age: 27±4 years; BMI: 23.0±2.5 kg/m 2 ; mean ± SD) and gave informed written consent prior to the biopsy. The experiments were carried out on subcultured (first pass) cells after growth to 80 to 90% confluence and subsequent differentiation to myotubes [14] . On day five of differentiation, the medium was replaced by the HEK293 supernatants and the myotubes were incubated therein for 48 h prior to RNA and protein analysis. Primary human skin fibroblasts were isolated from skin biopsies as formerly described [15] . The four donors who gave informed written consent prior to the biopsy were normal weight healthy Caucasians (2 men/2 women; age: 27± 4 years; BMI: 22.1±3.1 kg/m 2 ; mean ± SD). The fibroblasts were grown to subconfluence in DMEM supplemented with 2 mmol/l glutamine, 100 U/ml penicillin, 0.1 mg/ml streptomycin, 2.5 µg/ml amphotericin B, and 10% FCS and, thereafter, incubated with HEK293 supernatants for 48 h. HepG2 hepatoma cells were cultured in minimum essential medium Eagle containing non-essential amino acids supplemented with 2 mmol/l glutamine, 1 mmol/l pyruvate, 100 U/ml penicillin, 0.1 mg/ml streptomycin, and 10% FCS. At subconfluence, the cells were incubated and assayed as described for fibroblasts and in vitro differentiated myotubes. The study was approved by the local ethics committee.
Production of HEK293 supernatants. Untransfected human embryonic kidney HEK293 cells and the HEK293 cell line stably transfected with a haemagglutinin (HA)-tagged human adiponectin cDNA were grown in DMEM/Ham's nutrient mixture F-12 (1:1) supplemented with 2 mmol/l glutamine, 100 U/ml penicillin, 0.1 mg/ml streptomycin, and 10% FCS. Having reached confluence, the cells were shifted to FCSreduced medium (as above but containing only 0.5% FCS). This medium was renewed every 24 h. The medium conditioned during the first 24 h was discarded. The following 24-h conditioned media were cleared by centrifugation (700 g, 7 min) and collected over a period of 18 days.
Immunoblotting of adiponectin.
Qualitative and quantitative immunoblotting of adiponectin in HEK293 supernatants was done as described [16] . For detection of adiponectin in human myotube cultures, cells were washed and scraped off in PBS containing 1 mmol/l EDTA, 1 mmol/l phenylmethylsulfonylfluoride, 10 µg/ml aprotinin, 0.5 µg/ml leupeptin, and 0.7 µg/ml pepstatin. Thereafter, the cells were lysed on ice by sonication and the lysates were cleared by centrifugation. 100 µg of total cell lysate, as determined by the Bradford method, were subjected to gel electrophoresis and immunoblotting.
RT-PCR. RNA was isolated with peqGOLD TriFast according to the manufacturer's instructions. Total RNA treated with RNase-free DNase I was transcribed into cDNA using AMV reverse transcriptase and the first strand cDNA kit from Roche Diagnostics. Total RNA from visceral adipose tissue served as standard for in vivo adiponectin mRNA expression. Quantitative PCR was carried out with SYBR Green I dye on a high speed thermal cycler with integrated microvolume fluorometer according to the instructions of the manufacturer. The PCR conditions are given in Table 1 .
Quantification of adiponectin. Preparation of total cell lysates and determination of cellular protein were carried out as described. The adiponectin concentration was determined in 100 µl aliquots in triplicate by radioimmunoassay. Adiponectin contents of myotube lysates are given as ng adiponectin/mg cell protein. 
Results
Adiponectin content of HEK293 supernatants. The control supernatant of untransfected and the supernatant of HEK293 cells stably transfected with the HAtagged human adiponectin cDNA were subjected to Western blotting. Adiponectin was not detectable in the control supernatant of wild-type HEK293 cells by this method. By contrast, the HEK293 adiponectin transfectant produced a supernatant enriched with human recombinant adiponectin-HA (Fig. 1) . In this supernatant, an adiponectin concentration of 1.05 µg/ml was determined by the quantitative immunoblotting method.
Adiponectin supernatant-induced changes in myotube gene expression.
To investigate whether the expression of selected genes involved in muscle glucose and fatty acid metabolism as well as energy homeostasis is specifically altered by adiponectin, we treated in vitro differentiated human myotubes from eight different donors with the above mentioned supernatants. During the 48-h incubation period, both supernatants affected neither morphology nor viability of the myotube cultures. The expression of PPARγ1, PPARγ coactivator 1 (PGC-1), GLUT-1, GLUT-4, CD36/fatty acid transporter (FAT), FATP-1, muscle fatty acid binding protein (mFABP), PPARα, and uncoupling protein 3 (UCP-3) did not show significant differences when cells were treated with HEK293 adiponectin supernatant versus control supernatant (Table 2) . We also tested whether adiponectin modulates expression of its own gene in muscle cells. Adiponectin mRNA expression of in vitro differentiated human myotubes incubated with the control supernatant ranged at the detection limit. However, the adiponectin supernatant induced a 90-fold increase on average in adiponectin mRNA in these myotubes (Table 2) . This effect was consistently seen in myotube cultures from all eight donors. To exclude that this signal originates from the adiponectin supernatant, we carried out additional RT-PCR with a reverse primer directed against the HA-tag. Whereas the HEK293 adiponectin transfectant produced a signal corresponding to HAtagged recombinant adiponectin, human myotubes treated with adiponectin supernatant did not (n=4, data not shown). The amount of myotube adiponectin mRNA after exposure to the adiponectin supernatant reached 0.25±0.04% of the adiponectin mRNA con- tent of visceral adipose tissue. To verify that human myotubes indeed express adiponectin, we analysed total myotube lysates from four donors by immunoblotting. The adiponectin supernatant induced amounts of endogenous adiponectin protein that ranged at the detection limit of this method but were visible in myotube cultures from three donors (I, III, and IV) (Fig. 2) . By radioimmunoassay, adiponectin protein expression was found to be on average increased 8.3-fold in myotubes exposed to adiponectin supernatant compared with control supernatant (29.7±6.7 ng/mg vs 3.5±0.6 ng/mg, n=4, p<0.05).
Adiponectin, FATP-1, and PPARα mRNA expression in skin fibroblasts and HepG2 cells. The adiponectinenriched HEK293 supernatant increased adiponectin mRNA expression in human skin fibroblasts and HepG2 cells as well (Fig. 3A) . In contrast to the situation in myotubes, however, the amount of adiponectin mRNA in fibroblasts and hepatoma cells was still at the detection limit, even after incubation with the adiponectin supernatant. Furthermore, in fibroblasts and HepG2 cells the mRNA expression of adiponectin's hypothetical downstream targets FATP-1 and PPARα was unchanged, as was seen in human myotubes (Fig. 3B,C) .
Discussion
In mice, it was shown that adiponectin has insulin-sensitizing properties by reduction of free fatty acids in plasma [5, 6] , elevation of skeletal muscle fatty acid oxidation [1, 5] , and enhancement of insulin's suppressive action on hepatic gluconeogenesis [3, 4] . With regard to its lipid-lowering function, it was speculated that adiponectin increases the uptake of free fatty acids into muscle via FATP-1 [6] and fatty acid oxidation by PPARα-dependent induction of fatty acid-oxidizing enzymes [1] . Therefore, we examined here the expression of its hypothetical downstream signalling elements, i.e. FATP-1 and PPARα, in human myotubes, skin fibroblasts, and HepG2 cells after treatment with an adiponectin-containing HEK293 supernatant. In contrast to the in vivo findings in adiponectin-knockout [6] and lipoatrophic mice [1] , neither FATP-1 nor PPARα were induced at the mRNA level by adiponectin in the human cell types tested. This raises the possibility that adiponectin exerts its effects on skeletal muscle expression of FATP-1 and PPARα indirectly. Alternatively, differences in the signalling mechanisms of adiponectin between mice and humans might underlie this discrepancy. Furthermore, we studied the effect of the adiponectin-enriched supernatant on eight other genes implicated in glucose and lipid metabolism in human myotubes. This treatment selectively upregulated the expression of the adiponectin gene, whereas the other genes were unaffected. This opens the possibility that in muscle cells adiponectin can initiate an autocrine loop allowing continuous cellular stimulation by adiponectin which, in turn, might be a prerequisite for the maintainance of muscle cell insulin sensitivity. Expression of adiponectin mRNA and protein in myotubes was most probably not due to contamination of the myotube cultures with adipocytes since (i) parallel cultures of comparable purity did not show adiponectin expression after exposure to the control supernatant, and (ii) myotubes incubated with thiazolidinediones, potent adipogenic agents and strong inducers of adiponectin gene expression, did not show elevated adiponectin expression. Therefore, it is suggested that adiponectin expression can be induced in non-adipose cells. The increase in adiponectin mRNA could not be attributed to contamination with fibroblasts either because human skin fibroblasts exhibited at least 20-fold lower adiponectin mRNA expression than myotube cultures after incubation with the adiponectin supernatant. Therefore, we conclude that adiponectin expression is specifically inducible in muscle cells. The maximum adiponectin mRNA content reached in myotubes is lower than that obtained in visceral adipose tissue. However, the local efficacy might still be high since it is directly acting on the myotubes. Furthermore, the amounts of adiponectin mRNA reached by myotubes are well in the range of in vitro cell culture models since similar amounts were obtained with 3T3-L1 adipocytes (data not shown). In conclusion, we show here that adiponectin gene expression is not necessarily restricted to adipocytes but is also inducible in skeletal muscle cells.
